Talha Badar and Francesca Palandri/LinkedIn
Jun 12, 2026, 16:13
Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X:
“Excellent talk by Dr. Francesca Palandri on ET and PV at EHA 2026
Key takeaways:
Hydroxyurea remains the main 1st-line cytoreductive therapy, but care is increasingly individualized.
Emerging directions:
- Hepcidin modulation in PV, rusfertide and TMPRSS6 inhibitors
- CALR-targeted therapy, mAb and bispecific T-cell engagers
- Multidisciplinary care, including CV risk, fertility, dermatology, thrombosis, QoL
The future of MPN care is moving beyond count control toward disease biology, iron regulation, immune targeting, and patient-centered care.”
Stay updated with Hemostasis Today.
-
Jun 12, 2026, 16:12Miguel Gómez Álvarez: The Evidence on Disease Burden in PNH
-
Jun 12, 2026, 16:11Shinya Goto: The Japanese Investigators Behind Tranexamic Acid
-
Jun 12, 2026, 16:10Rahul Kumar: Improved Chemotherapy Delivery Is Meaningful Only When It Improves Patient Outcomes
-
Jun 12, 2026, 15:24A Practical Guide to Living Well with ITP – ITP Support Association
-
Jun 12, 2026, 15:16Courtney Lawrence: The AABB Bulletin on Neonatal Red Blood Cell Transfusion and Mannitol Exposure is Now Released
-
Jun 12, 2026, 15:05Sukanto Paul: Therapeutic Plasma Exchange as an Extracorporeal Liver Support Therapy
-
Jun 12, 2026, 14:40Daniel Auclair: Hematocure Team Shines at EHA 2026
-
Jun 12, 2026, 14:27Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
-
Jun 12, 2026, 14:15Shahram Kordasti: A Well-Deserved Honor at EHA 2026